spironolactone has been researched along with Hepatocellular Carcinoma in 4 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Coexistent hepatocellular carcinoma (HCC) was the only significant predictive variable that attenuated the efficacy of TLV." | 5.46 | Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. ( Goya, T; Kato, M; Kohjima, M; Kotoh, K; Masumoto, A; Miyazaki, M; Motomura, K; Senjyu, T; Tanaka, K; Yada, M, 2017) |
| "25% salt in drinking water improved body weight reduction associated with sodium and water retention in hepatocellular carcinoma rats, which was suppressed by treatment with spironolactone, a mineralocorticoid receptor antagonist." | 4.12 | Hepatocellular carcinoma induces body mass loss in parallel with osmolyte and water retention in rats. ( Kidoguchi, S; Kitada, K; Kittikulsuth, W; Kobara, H; Masaki, T; Nakajima, K; Nakano, D; Nishiyama, A; Ohsaki, H; Takahashi, K; Titze, J; Yokoo, T, 2022) |
| "Coexistent hepatocellular carcinoma (HCC) was the only significant predictive variable that attenuated the efficacy of TLV." | 1.46 | Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. ( Goya, T; Kato, M; Kohjima, M; Kotoh, K; Masumoto, A; Miyazaki, M; Motomura, K; Senjyu, T; Tanaka, K; Yada, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kidoguchi, S | 1 |
| Kitada, K | 1 |
| Nakajima, K | 1 |
| Nakano, D | 1 |
| Ohsaki, H | 1 |
| Kittikulsuth, W | 1 |
| Kobara, H | 1 |
| Masaki, T | 1 |
| Yokoo, T | 1 |
| Takahashi, K | 1 |
| Titze, J | 1 |
| Nishiyama, A | 1 |
| Miyazaki, M | 1 |
| Yada, M | 1 |
| Tanaka, K | 1 |
| Senjyu, T | 1 |
| Goya, T | 1 |
| Motomura, K | 1 |
| Kohjima, M | 1 |
| Kato, M | 1 |
| Masumoto, A | 1 |
| Kotoh, K | 1 |
| Lee, HJ | 1 |
| Rho, J | 1 |
| Gui, SR | 1 |
| Kim, MK | 1 |
| Lee, YK | 1 |
| Lee, YS | 1 |
| Kim, JE | 1 |
| Cho, E | 1 |
| Cho, M | 1 |
| Hwang, TH | 1 |
| Massaad, C | 1 |
| Lombès, M | 1 |
| Aggerbeck, M | 1 |
| Rafestin-Oblin, ME | 1 |
| Barouki, R | 1 |
4 other studies available for spironolactone and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Hepatocellular carcinoma induces body mass loss in parallel with osmolyte and water retention in rats.
Topics: Aldosterone; Animals; Carcinoma, Hepatocellular; Diethylnitrosamine; Liver Neoplasms, Experimental; | 2022 |
Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weig | 2017 |
Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines.
Topics: Aldosterone; Amiloride; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Hydrocortisone | 2011 |
Cell-specific, promoter-dependent mineralocorticoid agonist activity of spironolactone.
Topics: Aldosterone; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Mifepristone; Prom | 1997 |